New patent for the drug Xellia Pharms VANCOMYCIN – DrugPatentWatch
Annual Drug Patent Expiration for VANCOMYCIN
Vancomycin is a drug marketed by Xellia Pharms Aps, Akorn, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Strides Pharma, Watson Labs, Alkem Labs Ltd, Aspiro, Emcure Pharms Ltd, Eugia Pharma, Gland Pharma Ltd, Hainan Poly, Hainan Poly Pharm, Hikma, Hikma Pharms, Hospira, Hospira Inc, Knack, Meitheal, Mylan Labs Ltd, Pharm Assoc, Sagent Pharms, Sandoz, Sandoz Inc, Teva Pharms Usa, and Samson Medcl and are included in the forty-nine NDAs. It is available from a single supplier. There are five patents protecting this drug.
VANCOMYCIN drug price trends.
This drug has thirty-four patent family members in twenty-seven countries.
The generic ingredient in VANCOMYCIN is vancomycin hydrochloride. One registered supplier for this compound. Additional details are available on the vancomycin hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published in New patent for the drug Xellia Pharms VANCOMYCIN